新型冠状病毒肺炎所致肺纤维化的抗纤维化治疗：病例报告
Anti-fibrotic Treatment for Pulmonary Fibrosis Induced by COVID-19: A Case Presentation.
作者信息
Sakızcı Uyar Bahar, Ensarioğlu Kerem, Kurt E Bahar, Özkan Derya, Özbal Güneş Serra
机构信息
Department of Anesthesiology and Reanimation, University of Health Sciences, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey.
Department of Pulmonary Medicine, University of Health Sciences, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey.
出版信息
Turk J Anaesthesiol Reanim. 2022 Jun;50(3):228-231. doi: 10.5152/TJAR.2021.20450.
Coronavirus disease 19 infection clinical presentation varies from asymptomatic cases to acute respiratory distress syndromes. In some cases, pulmonary fibrosis is observed after or during the disease. Pirfenidone is an agent approved for the treatment of idiopathic pulmonary fibrosis. Here we report a patient treated with pirfenidone for pulmonary fibrosis related to coronavirus disease 19.
新型冠状病毒肺炎感染的临床表现从无症状病例到急性呼吸窘迫综合征不等。在某些情况下，疾病期间或之后会观察到肺纤维化。吡非尼酮是一种被批准用于治疗特发性肺纤维化的药物。在此，我们报告一名使用吡非尼酮治疗与新型冠状病毒肺炎相关的肺纤维化患者。
Zotero 插件